Atossa Therapeutics Inc
Veridion Score
Composite trend over time
Why is ATOS moving today?
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ATOS.
ATOS insider activity
Atossa Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | 2026-01-20 | QUAY STEVEN C | Insider | buy | $0.60 | 950,000 | 950,000 | $573K | SEC Form 4 |
| 2026-01-22 | 2026-01-20 | QUAY STEVEN C | Insider | buy | $0.60 | 950,000 | 950,000 | $573K | SEC Form 4 |
ATOS contract awards, year to date.
Public federal awards linked to this ticker.
ATOS lobbying filings, year to date.
Registered lobbying filings matched to Atossa Therapeutics Inc.